Mateos M-V, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine D-L, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica [Internet]. 2014May31 [cited 2026Nov.3];99(6):1114-22. Available from: https://haematologica.org/article/view/7054